Armada Acquisition III agrees to combine with Brains Bioceutical
AACI•Armada Acquisition III agreed to combine with Brains Bioceutical at an implied pre-money equity valuation of approximately $750 million. The combined company is expected to trade on Nasdaq as Brains Therapeutics under the ticker BAPI, with closing expected in the second quarter of 2027.
1. Proposed combination
Armada Acquisition III agreed to combine with Brains Bioceutical at an implied pre-money equity valuation of approximately $750 million. Existing Brains shareholders are expected to roll 100% of their equity into the combined company.
2. Expected closing
The combined company is expected to operate as Brains Therapeutics, with common shares trading on Nasdaq under the ticker BAPI. Closing is expected in the second quarter of 2027, subject to shareholder approvals and other closing conditions.
